PNIBLOG

Central nervous system (CNS) malignancies are a highly heterogeneous group of cancers characterized by an extensive spectrum of disease. Ensuring that the patient with a CNS tumor is introduced to palliative care at the time of diagnosis is where the neuro-oncology nurse navigator can have a substantial impact. Read more in this great article featuring Advanced Practice Registered Nurse and Director of Center for Quality Outcomes & Research, Marlon Saria, PhD, RN.

Seattle Science Foundation Fellows Course 2019

Keyhole surgery is the concept of safely removing brain, skull base and pituitary tumors through smaller, more precise openings that minimize collateral damage to surrounding scalp, brain, blood vessels and nerves. A majority of these tumors can now be removed via one of the several keyhole approaches available nowadays, using a small craniotomy (bony skull opening) or an approach through the nostrils. These approaches are technically demanding, require specialized instrumentation, significant surgical expertise and are not appropriate for all tumors. Find out more.

ct-DNA

A recently published paper by Pacific Neuroscience Institute researchers suggests a promising new approach for a biopsy-free method to identify primary brain tumor genetics for personalized treatment options.

Neurosurgery Fellowship at Pacific Neuroscience Institute

What is it like to be a brain surgeon? Take a look behind the scenes and follow a young doctor through his day as a neurosurgery fellow in a busy practice at Pacific Neuroscience Institute in Santa Monica, California.

Stem cell therapy and brain health

Clinical trials using stem cells have shown promising early results as cellular therapies in regenerative medicine, as well as in potential anti-cancer applications. Read more about Dr. Achal Singh Achrol’s neurosurgery clinical trials program and this leading-edge technology.

Glioblastoma MDNA55 Trial Medicenna

Pacific Neuroscience Institute, the leading enrollment site for the MDNA55 clinical trial for Glioblastoma, is still open and enrolling eligible patients. This innovative phase 2 study is for the minimally invasive convection-enhanced delivery (CED) of a new bioengineered targeted therapeutic, MDNA55, in adults with recurrent or progressive glioblastoma. Read more.

Clinical Trials at Pacific Neuroscience Institute

Pacific Neuroscience Institute opens up two new clinical trials this month, one in Essential Tremor and one in Glioblastoma. Find out more about these new trials as well as the other available open neurological studies.